Wuhan Healthgen Biotechnology Corp. (SHSE: 688765)
Health Care · Biotechnology · CN
CN¥37.86
-4.97% today · -58.4% 1Y
Wuhan Healthgen Biotechnology Corp. (SHSE: 688765) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.02B.
Over the last twelve months the share price has lost 58.4%, trading between 32.61 and 132.03.
Tweenvest scores Wuhan Healthgen Biotechnology Corp. across four factors: quality 41/100, value 65/100, growth 100/100. Its strongest factor is growth.
688765 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.02B
- Revenue (TTM)
- $3.29M
- P/E
- —
- EPS
- -0.59
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CN¥132.03
- 52-week low
- CN¥32.61
- Avg volume (3M)
- —
- Shares outstanding
- 357.50M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Mineralys Therapeutics, Inc.NasdaqGS: MLYS | $2.07B | $22.31 | -4.54% |
| AlvotechNasdaqGM: ALVO | $2.06B | $5.52 | -4.58% |
| Vericel CorporationNasdaqGM: VCEL | $2.05B | $40.28 | +0.45% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $2.05B | CN¥26.60 | -2.35% |
| Genus plcLSE: GNS | $2.02B | £22.72 | -0.35% |
| Palvella Therapeutics, Inc.NasdaqGM: PVLA | $2.00B | $132.89 | -4.24% |
| ABL Bio Inc.KOSDAQ: A298380 | $2.00B | ₩48,000.00 | -6.61% |
| ADARx Pharmaceuticals, Inc.NasdaqGS: ADRX | $1.99B | $17.78 | 0.00% |
Figures last refreshed Oct 11, 2026.